Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 29, 2026 03:17 ET | Source: InnoCare Pharma

Study Results of Novel TYK2 Inhibitor Soficitinib in Patients with AD Published by JAMA Dermatology

Soficitinib demonstrated a favorable safety profile and encouraging efficacy in treating patients with moderate-to-severe AD.